 |
13 Diseases |  |
52 Trials |
|
52 Trials |  |
3235 News |  |
| «12...25262728293031323334353637» |
- | Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Alecensa (alectinib) / Roche
Journal: Emerging Treatment for ALK-positive Lung Cancer. (Pubmed Central) - May 31, 2017
However, there remain many issues in routine clinical application including the burden placed on the patients by serial biopsies and the risks of repeat invasive procedures. Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors.
- |||| Enrollment open, Trial initiation date, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - May 18, 2017
P2, N=119, Recruiting, Sponsor: University College, London
Future studies are needed to validate the usage of non- or minimally invasive tests and to determine the optimal orders of utilizing different ALK inhibitors. Not yet recruiting --> Recruiting | Initiation date: Jan 2017 --> May 2017
- | New P1/2 trial: NCT Neuro Master Match - N (clinicaltrials.gov) - May 18, 2017
P1/2, N=350, Not yet recruiting, Sponsor: University Hospital Heidelberg
- ||||| Alecensa (alectinib) / Roche
New P2 trial: ATALK: A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (clinicaltrials.gov) - May 15, 2017
P2, N=73, Not yet recruiting, Sponsor: Hoffmann-La Roche
- | Alecensa (alectinib) / Roche
Journal: The role of alectinib in the treatment of advanced ALK-rearranged non-small-cell lung cancer. (Pubmed Central) - May 12, 2017
Expert commentary: Second generation ALK inhibitors as alectinib and ceritinib can overcome crizotinib-resistant mutations and improve central nervous system control. Novel third-generation inhibitors and combination of agents give hope of achieving an even longer disease control in the next decade.
- ||||| Alecensa (alectinib) / Roche
Enrollment closed, Metastases: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib (clinicaltrials.gov) - May 9, 2017
P3, N=120, Active, not recruiting, Sponsor: Hoffmann-La Roche
Novel third-generation inhibitors and combination of agents give hope of achieving an even longer disease control in the next decade. Recruiting --> Active, not recruiting
- ||||| Alecensa (alectinib) / Roche
New P1/2 trial: A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer (clinicaltrials.gov) - Apr 27, 2017
P1/2, N=78, Not yet recruiting, Sponsor: Dana-Farber Cancer Institute
- Zykadia (ceritinib) / Novartis
Trial primary completion date: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Mar 28, 2017
P2, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting Trial primary completion date: Nov 2017 --> Aug 2017
- |||| Alecensa (alectinib) / Roche
Trial primary completion date, Metastases: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib (clinicaltrials.gov) - Mar 16, 2017
P3, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Nov 2017 --> Aug 2017 Trial primary completion date: Apr 2019 --> Jan 2017
- | Alecensa (alectinib) / Roche
Journal: Alectinib for the management of ALK-positive non-small cell lung cancer brain metastases. (Pubmed Central) - Mar 10, 2017
Trial primary completion date: Apr 2019 --> Jan 2017 No abstract available
- | Alecensa (alectinib) / Roche
Trial completion: Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib (clinicaltrials.gov) - Feb 23, 2017
P1, N=48, Completed, Sponsor: Hoffmann-La Roche
No abstract available Recruiting --> Completed
- |||| Alecensa (alectinib) / Roche
Trial primary completion date, Metastases: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib (clinicaltrials.gov) - Nov 2, 2016
P3, N=120, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Completed Trial primary completion date: Oct 2018 --> Apr 2019
- ||| Alecensa (alectinib) / Roche
Trial completion, Phase classification: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (clinicaltrials.gov) - Sep 27, 2016
P=N/A, N=129, Completed, Sponsor: Genentech, Inc.
Trial primary completion date: Oct 2018 --> Apr 2019 Active, not recruiting --> Completed | Phase classification: P3 --> PN/A
- Zykadia (ceritinib) / Novartis
Trial primary completion date: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Sep 12, 2016
P2, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Phase classification: P3 --> PN/A Trial primary completion date: Apr 2018 --> Nov 2017
- |||||||||| Alecensa (alectinib) / Roche
New P3 trial, Metastases: A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jul 20, 2016
P3, N=183, Recruiting, Sponsor: Hoffmann-La Roche
- || Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
Phase classification, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 1, 2016
P1b, N=53, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2018 --> Nov 2017 Phase classification: P1 --> P1b | Trial primary completion date: Sep 2015 --> Dec 2018
- ||| Enrollment change, Trial initiation date, Trial primary completion date, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - Mar 9, 2016
P2, N=119, Not yet recruiting, Sponsor: University College, London
Phase classification: P1 --> P1b | Trial primary completion date: Sep 2015 --> Dec 2018 N=157 --> 119 | Initiation date: Jan 2016 --> Jan 2017 | Trial primary completion date: Jun 2022 --> Jan 2023
- | Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
Enrollment open, Metastases: Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer (clinicaltrials.gov) - Feb 17, 2016
P1/2, N=43, Recruiting, Sponsor: Massachusetts General Hospital
N=157 --> 119 | Initiation date: Jan 2016 --> Jan 2017 | Trial primary completion date: Jun 2022 --> Jan 2023 Not yet recruiting --> Recruiting
- || Alecensa (alectinib) / Roche
Trial primary completion date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 12, 2016
P2, N=133, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2015 --> Oct 2014
- ||||| Alecensa (alectinib) / Roche
Enrollment closed, Trial primary completion date, Metastases: ALEX: A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants (clinicaltrials.gov) - Feb 11, 2016
P3, N=303, Active, not recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Dec 2015 --> Oct 2014 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Mar 2017
- ||||| Alecensa (alectinib) / Roche
Enrollment closed: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (clinicaltrials.gov) - Feb 2, 2016
P3, N=129, Active, not recruiting, Sponsor: Genentech, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2017 --> Mar 2017 Recruiting --> Active, not recruiting
- | Alecensa (alectinib) / Roche
New P1 trial: Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib (clinicaltrials.gov) - Dec 3, 2015
P1, N=48, Recruiting, Sponsor: Hoffmann-La Roche
- |||||||||| Alecensa (alectinib) / Roche
New P3 trial, Metastases: Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib (clinicaltrials.gov) - Nov 14, 2015
P3, N=120, Recruiting, Sponsor: Hoffmann-La Roche
- || Alecensa (alectinib) / Roche
Trial initiation date: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - Oct 22, 2015
P1, N=97, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Initiation date: Aug 2014 --> Feb 2014
- |||| Alecensa (alectinib) / Roche
Trial primary completion date: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (clinicaltrials.gov) - Oct 2, 2015
P3, N=120, Recruiting, Sponsor: Genentech, Inc.
Initiation date: Aug 2014 --> Feb 2014 Trial primary completion date: Nov 2016 --> Apr 2016
- |||| Alecensa (alectinib) / Roche
Trial primary completion date: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (clinicaltrials.gov) - Sep 24, 2015
P3, N=120, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Nov 2016 --> Apr 2016 Trial primary completion date: Apr 2016 --> Nov 2016
- || Tecentriq (atezolizumab) / Roche, Alecensa (alectinib) / Roche
Enrollment change, Combination therapy, PD(L)-1 Biomarker, Metastases: A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Sep 4, 2015
P1, N=53, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Apr 2016 --> Nov 2016 N=32 --> 53
- ||| Trial initiation date, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - Aug 21, 2015
P2, N=157, Not yet recruiting, Sponsor: University College, London
N=32 --> 53 Initiation date: Jun 2015 --> Jan 2016
- | Avastin (bevacizumab) / Roche, Alecensa (alectinib) / Roche
New P1/2 trial, Metastases: Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 13, 2015
P1/2, N=43, Not yet recruiting, Sponsor: Massachusetts General Hospital
- | Zykadia (ceritinib) / Novartis
Enrollment open: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - Aug 4, 2015
P2, N=20, Recruiting, Sponsor: Novartis Pharmaceuticals
Initiation date: Jun 2015 --> Jan 2016 Not yet recruiting --> Recruiting
- ||| Alecensa (alectinib) / Roche
Enrollment change: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jun 11, 2015
P2, N=152, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting N=107 --> 152
- ||| Alecensa (alectinib) / Roche
Enrollment closed: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Jun 1, 2015
P2, N=154, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=107 --> 152 Recruiting --> Active, not recruiting
- | Zykadia (ceritinib) / Novartis
New P2 trial: LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib. (clinicaltrials.gov) - May 21, 2015
P2, N=20, Not yet recruiting, Sponsor: Novartis Pharmaceuticals
- ||| Alecensa (alectinib) / Roche
Enrollment closed: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - May 12, 2015
P2, N=107, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||| Alecensa (alectinib) / Roche
Enrollment open, Enrollment change, Trial initiation date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Apr 6, 2015
P2, N=85, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=115 --> 85 | Initiation date: Sep 2013 --> Apr 2013
- ||| Alecensa (alectinib) / Roche
Enrollment closed, Enrollment change, Trial initiation date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Mar 10, 2015
P2, N=115, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting | N=115 --> 85 | Initiation date: Sep 2013 --> Apr 2013 Recruiting --> Active, not recruiting | N=85 --> 115 | Initiation date: Apr 2013 --> Sep 2013
- ||| Alecensa (alectinib) / Roche
Enrollment closed: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Mar 10, 2015
P2, N=155, Active, not recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=85 --> 115 | Initiation date: Apr 2013 --> Sep 2013 Recruiting --> Active, not recruiting
- |||| Alecensa (alectinib) / Roche
Enrollment open, Enrollment change: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 24, 2015
P2, N=85, Recruiting, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting Active, not recruiting --> Recruiting | N=115 --> 85
- ||| Alecensa (alectinib) / Roche
Enrollment closed, Enrollment change: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Feb 20, 2015
P2, N=115, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting | N=115 --> 85 Recruiting --> Active, not recruiting | N=85 --> 115
- Alecensa (alectinib) / Roche
Trial completion: A Study of the Elimination, Pharmacokinetics, and Metabolism of RO5424802 (clinicaltrials.gov) - Feb 20, 2015
P1, N=6, Completed, Sponsor: Hoffmann-La Roche
Recruiting --> Active, not recruiting | N=85 --> 115 Terminated --> Completed
- |||| Alecensa (alectinib) / Roche
Enrollment open, Enrollment change, Trial primary completion date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Jan 28, 2015
P2, N=85, Recruiting, Sponsor: Hoffmann-La Roche
Terminated --> Completed Active, not recruiting --> Recruiting | N=115 --> 85 | Trial primary completion date: Sep 2015 --> Dec 2015
- ||||| New P2 trial, Heterogeneity, PD(L)-1 Biomarker: DARWIN II: Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity (clinicaltrials.gov) - Dec 11, 2014
P2, N=157, Not yet recruiting, Sponsor: University College, London
- || Alecensa (alectinib) / Roche
Trial primary completion date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 25, 2014
P2, N=115, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting | N=115 --> 85 | Trial primary completion date: Sep 2015 --> Dec 2015 Trial primary completion date: Dec 2015 --> Sep 2015
- | Alecensa (alectinib) / Roche
Enrollment open: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (clinicaltrials.gov) - Nov 25, 2014
P3, N=120, Recruiting, Sponsor: Genentech, Inc.
Trial primary completion date: Dec 2015 --> Sep 2015 Not yet recruiting --> Recruiting
- || Alecensa (alectinib) / Roche
Trial primary completion date: A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) (clinicaltrials.gov) - Nov 18, 2014
P2, N=115, Active, not recruiting, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Recruiting Trial primary completion date: Sep 2015 --> Dec 2015
- || Alecensa (alectinib) / Roche
Enrollment change, Trial initiation date, Trial primary completion date: A Cross-over Study Examining the Bioequivalence of 3 Test Formulations to a Reference Formulation of Alectinib (RO5424802) in Healthy Volunteers (clinicaltrials.gov) - Nov 4, 2014
P1, N=97, Completed, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2015 --> Dec 2015 N=49 --> 97 | Initiation date: Mar 2014 --> Aug 2014 | Trial primary completion date: Apr 2014 --> Sep 2014
- || Alecensa (alectinib) / Roche
New P3 trial: Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor Therapy (clinicaltrials.gov) - Oct 22, 2014
P3, N=120, Not yet recruiting, Sponsor: Genentech, Inc.
- Alecensa (alectinib) / Roche
Trial primary completion date: A Clinical Study Testing The Safety and Efficacy of CH5424802/RO5424802 in Patients With ALK Positive Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 17, 2014
P1/2, N=36, Active, not recruiting, Sponsor: Hoffmann-La Roche
N=49 --> 97 | Initiation date: Mar 2014 --> Aug 2014 | Trial primary completion date: Apr 2014 --> Sep 2014 Trial primary completion date: Sep 2014 --> Sep 2015
- |||| Alecensa (alectinib) / Roche
Enrollment open: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Sep 28, 2014
P2, N=130, Recruiting, Sponsor: Hoffmann-La Roche
Trial primary completion date: Sep 2014 --> Sep 2015 Active, not recruiting --> Recruiting
- ||| Alecensa (alectinib) / Roche
Enrollment closed: A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment (clinicaltrials.gov) - Sep 11, 2014
P2, N=146, Active, not recruiting, Sponsor: Hoffmann-La Roche
Active, not recruiting --> Recruiting Recruiting --> Active, not recruiting